All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
7 warning events since 2017; the latest 2025-04-10.
From the record
Xenetic Biosciences, Inc.'s filings since 2017 show 7 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 6 times, the latest 2022-12-02); an auditor change (8-K item 4.01, the latest 2025-04-10) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-0.1% a year over 10 filed years; profitable in 0 of 10.
From the record
Xenetic Biosciences, Inc.'s 10 filed years say what it did: revenue went from $3 million in fiscal 2016 to $3 million in fiscal 2025, down 0.1% a year; it rose in 6 of 8 years; the deepest fall was 100% from fiscal 2017 to fiscal 2018; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 7.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Xenetic Biosciences, Inc.'s shareholder treatment is put at 7.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 28% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -36%: lost 36¢ per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Xenetic Biosciences, Inc. lost about 36 cents for every dollar of shareholders' money. Leverage: it owed about 12 cents per dollar of assets, and net share issuance: its share count grew 10.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 50% of 315 in its family; net margin -90.1%.
From the record
Xenetic Biosciences, Inc.'s standing among 315 graded names in its industry family: revenue of $3 million in fiscal 2025 ranks in the bottom 31% by size; a net margin of -90.1% ranks in the top 45%; revenue growth of 20.4% a year over the last 3 filed years ranks in the top 37% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 46% of 315 in its family for leadership; chief executive since 2024.
From the record
Xenetic Biosciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Parslow, James F (Interim CEO and CFO, as filed), filing under that title since 2024-06-21, 2.4 years (bottom 27% of its family); the 5 officers and directors filing in the last fifteen months have been on the record a median of 9.6 years (top 9%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 5 people in charge now (bottom 20%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 35% of 273 in its family for room to expand.
From the record
Xenetic Biosciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $8 million against no long-term debt tagged leaves 94.3% of its assets as net cash, top 5% of its family; cash from operations less capital spending is -76.8% of revenue (top 48%); research spending of 103% of revenue (bottom 49%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 43% of 306 in its family for growth drivers.
From the record
Xenetic Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 20.4% a year over the last three filed years against -0.1% over all 10, speeding up (top 13% of its family); the newest year grew 19.1% (top 39%); research spending grew -13.7% a year (bottom 24%) (its annual reports). Xenetic Biosciences, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 37% of 233 in its family for expectations against reality.
From the record
Xenetic Biosciences, Inc.'s newest year against its own record: revenue of $3 million in fiscal 2025 came in 1.6% below the $3 million its prior three years' pace pointed to (top 49% of its family); net income of $3 million against a prior three-year average of $5 million (top 34%); a net margin of -90.1% against losses larger than its revenue before (top 29%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made